Changes in adiposity and metabolic measures during medication switches to aripiprazole from other atypical antipsychotics

Trial Profile

Changes in adiposity and metabolic measures during medication switches to aripiprazole from other atypical antipsychotics

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Jun 2010

At a glance

  • Drugs Aripiprazole; Olanzapine; Quetiapine; Risperidone
  • Indications Schizophrenia
  • Focus Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 26 Jun 2010 Results presented at the 70th Annual Scientific Sessions of the American Diabetes Association.
    • 06 Apr 2010 Actual end date (1 Aug 2009) added as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top